News — AI supercycle headlines

Moby8d agoneutral

Evolus, Inc. Q1 2026 Earnings Call Summary

Moby summary of Evolus, Inc.'s Q1 2026 earnings call

MarketBeat8d agoneutral

Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year 2026 outlook for double-digit revenue growth and adjusted EBITDA profitability. First-quarter results

EOLS

Motley Fool8d agoneutral

Evolus (EOLS) Q2 2025 Earnings Call Transcript

David Moatazedi: Thank you, Nareg, and good afternoon, everyone. Internationally, the business continues to deliver strong performance and is increasingly contributing to our growth trajectory as we expand our global footprint in key markets.

EOLS

Simply Wall St.17d agoneutral

How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions

Evolus is back in focus after analysts revisited their price target framework, keeping the fair value unchanged at $14.67 per share. Some see the maintained target as confirmation that the core thesis is intact, while others read the previous $4 cut as a sign that expectations around long term revenue may have been reset. As you read on, you will see how to interpret this evolving analyst narrative and what to watch if you are tracking Evolus from here. Analyst Price Targets don't always...

EOLS

Simply Wall St.27d agoneutral

April 2026's Leading Growth Stocks With Insider Confidence

The United States market has shown robust performance, rising 3.4% over the last week and an impressive 35% over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.

EOLS

MarketBeat27d agoneutral

Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference

Evolus (NASDAQ:EOLS) executives told investors at Needham & Company’s 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as it expands beyond its flagship neurotoxin Jeuveau and scales its newer hyaluronic acid (HA) fill

EOLS

Exec Edge35d agoneutral

Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization

By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]

EOLS

MarketBeat58d agoneutral

Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference

Evolus (NASDAQ:EOLS) executives said they are seeing signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower recovery for dermal fillers amid changing consumer sentiment. Speaking at the Leerink Conference, CEO Dav

EOLS